Last reviewed · How we verify
MSC1936369B
At a glance
| Generic name | MSC1936369B |
|---|---|
| Also known as | Pimasertib |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (PHASE1, PHASE2)
- Trial of MSC1936369B in Subjects With Solid Tumors (PHASE1)
- Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus (PHASE1)
- Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma (PHASE2)
- Trial of Pimasertib in Hematological Malignancies (PHASE2)
- Relative Bioavailability of Pimasertib in Cancer Patients (PHASE1)
- Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer (PHASE1, PHASE2)
- Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSC1936369B CI brief — competitive landscape report
- MSC1936369B updates RSS · CI watch RSS
- Sanofi portfolio CI